Antimicrobial resistance (AMR) is a leading global public health threat that calls for coordinated action across multiple sectors. In 2024, country representatives at the UN General Assembly committed to creating the Independent Panel on Evidence for Action against AMR (IPEA). This initiative is aimed to bring together multidisciplinary experts to provide countries with evidence-based guidance on how to effectively address AMR. The IPEA is set to be established by the end of 2025.
How will the IPEA provide solutions that are representative of AMR in low, middle, and high resource settings? What are some potential challenges that the IPEA may face in its development stage? What are the short and long-term priorities of the IPEA?
We discuss all of this and more in Episode 7 of Unpacking AMR, hosted by GSL Director of Communications Demetria Tsoutouras, who she speaks with Dr. Iruka Okeke, a Professor of Pharmaceutical Microbiology, and Anthony McDonnell, a Policy Fellow in the Center for Global Development’s Global Health Team. The development of the IPEA is a step forward in addressing the complex and wide spanning concern of AMR.
All content for Unpacking AMR is the property of AMR Policy Accelerator and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Antimicrobial resistance (AMR) is a leading global public health threat that calls for coordinated action across multiple sectors. In 2024, country representatives at the UN General Assembly committed to creating the Independent Panel on Evidence for Action against AMR (IPEA). This initiative is aimed to bring together multidisciplinary experts to provide countries with evidence-based guidance on how to effectively address AMR. The IPEA is set to be established by the end of 2025.
How will the IPEA provide solutions that are representative of AMR in low, middle, and high resource settings? What are some potential challenges that the IPEA may face in its development stage? What are the short and long-term priorities of the IPEA?
We discuss all of this and more in Episode 7 of Unpacking AMR, hosted by GSL Director of Communications Demetria Tsoutouras, who she speaks with Dr. Iruka Okeke, a Professor of Pharmaceutical Microbiology, and Anthony McDonnell, a Policy Fellow in the Center for Global Development’s Global Health Team. The development of the IPEA is a step forward in addressing the complex and wide spanning concern of AMR.
In this episode of Unpacking AMR we explore the principles behind the SAFE AMR Governance Partnership. Join us in a conversation with Julianne Piper, Carly Ching, Isaac Weldon, and Jeremy Grimshaw while they highlight how a collaborative, One Health approach can help safeguard our global pool of antimicrobials for future generations.
Unpacking AMR
Antimicrobial resistance (AMR) is a leading global public health threat that calls for coordinated action across multiple sectors. In 2024, country representatives at the UN General Assembly committed to creating the Independent Panel on Evidence for Action against AMR (IPEA). This initiative is aimed to bring together multidisciplinary experts to provide countries with evidence-based guidance on how to effectively address AMR. The IPEA is set to be established by the end of 2025.
How will the IPEA provide solutions that are representative of AMR in low, middle, and high resource settings? What are some potential challenges that the IPEA may face in its development stage? What are the short and long-term priorities of the IPEA?
We discuss all of this and more in Episode 7 of Unpacking AMR, hosted by GSL Director of Communications Demetria Tsoutouras, who she speaks with Dr. Iruka Okeke, a Professor of Pharmaceutical Microbiology, and Anthony McDonnell, a Policy Fellow in the Center for Global Development’s Global Health Team. The development of the IPEA is a step forward in addressing the complex and wide spanning concern of AMR.
